Daniel V Runco, MD, MS

Daniel V Runco, MD, MS

Specialties

  • Children's Title: Attending Physician, Cancer and Blood Disorders Center
  • Academic Title: Assistant Professor, Department of Pediatrics, University of Washington School of Medicine
  • Research Center: Ben Towne Center for Childhood Cancer Research
  • On Staff Since: January 2024
"Everything we do as pediatric oncologists should make children live longer or live better – and ideally both. As a pediatric neuro-oncologist, I am thankful to be part of a multidisciplinary team focused solely on improving things for children with cancer and walking through the most difficult days with them and their families. As a researcher, I am passionate about advancing treatments and understanding childhood cancer so our patients can live longer, better lives. "

  • Biography

    Daniel Runco, MD, MS is a Pediatric Oncologist in the Brain Tumor Program at Seattle Children’s Hospital and Assistant Professor at the University of Washington School of Medicine. Dr. Runco joined the faculty in 2024 as a Clinician Scholar with research interests in childhood cancer cachexia. His research is focused around better understanding nutrition and body composition changes that occur during cancer treatment and how that impacts long term survival and quality-of-life. He continues to be active in national and international clinical trials and collaborative societies around treating childhood brain tumors and cancer cachexia.

    Board Certification(s)

    Pediatrics
    Pediatric Hematology-Oncology

    Education

    Emory University, Atlanta, GA
    Stritch School of Medicine, Maywood, IL

    Residency

    Indiana University Pediatrics Residency Program, Indianapolis, IN

    Fellowship

    Emory University School of Medicine, Atlanta, GA

    Clinical Interests

    Pediatric neuro-oncology, clinical trials, nutrition, supportive care

    Research Description

    Dr. Runco focuses on identifying, quantifying, and describing childhood cancer cachexia – the muscle loss, weight loss, and body composition changes that occur with a cancer diagnosis and treatment. In addition to better understanding mediators of cachexia, Dr. Runco hopes to identify potential therapeutic targets as in order to mitigate cachexia, improve on-time and optimal cancer therapy delivery, and improve long-term outcomes for survivors of childhood cancers. 

  • Patient Testimonials

    • {{ testimonial.displayName }}
      {{ testimonial.location }}
      {{ formatTestimonialDate(testimonial.date) }}

      {{ testimonial.testimony }}

  • Awards and Honors

    Award Name Award Description Awarded By Award Date
    {{ award.name }} {{ award.description }} {{ award.organization }} {{ award.displayDate }}

  • Publications

  • Presentations

    Presentation Title Event Location Date
    {{ presentation.title }} {{ presentation.presentedAt }} {{ presentation.location }} {{ presentation.displayDate }}

  • Research Funding

    Grant Title Grantor Amount Award Date
    {{ funding.title }} {{ funding.grantedBy }} {{ funding.amount }} {{ funding.displayDate }}

  • Clinical Trials and Research

    {{ item.t }}

    {{ item.st }}

    {{ item.obj }}

    Condition: {{ item.con }} Phase: {{ item.ph }} Clinicaltrials.gov ID: {{ item.nct }}

    No clinical trials found for Daniel V Runco, MD, MS.